MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-29-2026
NovaBay Pharmaceuticals DPO Ratio 2011-2026 | NBY
Annual DPO Ratio NovaBay Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 82.9 | 58.6 | 66.6 | 27.8 | 69.5 | 134 | 61.1 | 67.4 | 719 | 1.4 K | 3.77 K | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.77 K | 27.8 | 587 |
Quarterly DPO Ratio NovaBay Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64.8 | - | - | - | 87.8 | 133 | 110 | - | 135 | 66.8 | 138 | - | 63.7 | 62.2 | 81.3 | - | 100 | 77.3 | 114 | - | 51.4 | 13.5 | 49.7 | - | 75.3 | 75 | 118 | - | 151 | 105 | 185 | - | 81.6 | 60.9 | 71.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 185 | 13.5 | 90.9 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Esperion Therapeutics
ESPR
|
7.93 K | $ 3.13 | 0.39 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
148 | $ 45.86 | 3.23 % | $ 12.5 B | USA |
 |
Fortress Biotech
FBIO
|
400 | $ 2.51 | 2.03 % | $ 70 M | USA |
 |
Galapagos NV
GLPG
|
81.9 | $ 28.95 | 1.97 % | $ 2.69 B |  Belgium |
 |
Immuron Limited
IMRN
|
597 | $ 0.81 | 2.15 % | $ 6.7 M |  Australia |
 |
Ionis Pharmaceuticals
IONS
|
815 | $ 76.26 | 1.34 % | $ 12.2 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Kamada Ltd.
KMDA
|
106 | $ 8.25 | 0.49 % | $ 260 M |  Israel |
 |
Kymera Therapeutics
KYMR
|
46.6 | $ 85.73 | 3.65 % | $ 7.24 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
75.2 | $ 22.93 | 2.6 % | $ 3.8 B | USA |
 |
Liquidia Corporation
LQDA
|
209 | $ 42.33 | 5.48 % | $ 3.64 B | USA |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
MannKind Corporation
MNKD
|
108 | $ 4.01 | 40.03 % | $ 1.23 B | USA |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 23.48 | 0.26 % | $ 2.99 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |